Federal health officials have approved the first lower-cost copy of a biotech drug to reach the U.S. market, a long-awaited milestone that could generate billions in savings for insurers, doctors and patients.
Mar 6, 2015
0
9
(AP)—The Supreme Court ruled Wednesday that a state regulatory board made up mostly of dentists violated federal law against unfair competition when it tried to prevent lower-cost competitors in other fields from offering ...
Feb 25, 2015
1
4
According to the Centers for Disease Control and Prevention, two million people become infected with antibiotic resistant bacteria each year, leading to at least 23,000 deaths. And these infections cost a lot – US$20billion ...
Feb 9, 2015
0
8
Pfizer Inc.'s fourth-quarter profit fell by half as worsening generic competition and unfavorable currency rates reduced sales, and higher research and legal costs also reduced the bottom line.
Jan 27, 2015
0
2
In cell competition the strong eliminate the weak, thereby ensuring optimal tissue fitness. Molecular biologists at the University of Zurich and Columbia University have now demonstrated that the innate immune system plays ...
Dec 4, 2014
0
0
Medical practices in less competitive health-care markets charge more for services, according to a study conducted by researchers at the Stanford University School of Medicine and the National Bureau of Economic Research.
Oct 21, 2014
0
0
The European Union's antitrust authority says it has approved the $5.4 billion sale of Novartis' animal health division to U.S. pharmaceutical firm Eli Lilly.
Oct 3, 2014
0
0
The maker of the world's top-selling erectile dysfunction drug on Tuesday will begin airing the first Viagra TV commercial in America that targets the less-obvious sufferers of the sexual condition: women.
Sep 30, 2014
0
0
The success of an innovative design app competition, organised through our Centre for Pain Research, is cited in a recent Parliamentary Report on advances into assistive technology that could help the elderly and people living ...
Aug 29, 2014
0
0
Warfarin, the longtime standard treatment for atrial fibrillation, is facing competition from new options in the anticoagulant drug marketplace including dabigatran, rivaroxaban, and apixaban. A new study documents the rapid ...
Aug 19, 2014
0
0
